Compare IRT & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRT | CRNX |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.9B |
| IPO Year | 2009 | 2018 |
| Metric | IRT | CRNX |
|---|---|---|
| Price | $16.79 | $83.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 8 |
| Target Price | $20.45 | ★ $76.75 |
| AVG Volume (30 Days) | 3.0M | ★ 5.2M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.17% | N/A |
| EPS Growth | ★ 41.18 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $657,696,000.00 | $1,039,000.00 |
| Revenue This Year | $3.21 | $720.10 |
| Revenue Next Year | $3.54 | $184.67 |
| P/E Ratio | $68.10 | ★ N/A |
| Revenue Growth | ★ 2.76 | N/A |
| 52 Week Low | $14.60 | $25.83 |
| 52 Week High | $18.19 | $83.70 |
| Indicator | IRT | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 51.66 | 93.09 |
| Support Level | $16.60 | $41.42 |
| Resistance Level | $17.15 | N/A |
| Average True Range (ATR) | 0.35 | 1.38 |
| MACD | 0.00 | 5.72 |
| Stochastic Oscillator | 55.39 | 99.72 |
Independence Realty Trust Inc is a real estate investment trust (REIT) that acquires, owns, operates, improves and manages multifamily apartment communities across non-gateway U.S. markets. It owns and operates multifamily apartment properties, across non-gateway U.S markets, including Atlanta, Columbus, Dallas, Denver, Houston, Indianapolis, Nashville, Oklahoma City, Raleigh-Durham, and Tampa. The company is focused on gaining scale within key amenity-rich submarkets that offer school districts, retail, and various employment centers.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.